A recombinant human monoclonal anti-R7V antibody as a potential therapy for HIV infected patients in failure of HAART

Hum Antibodies. 2007;16(3-4):73-85.

Abstract

The construction of a recombinant antibody directed against the cellular epitope R7V acquired by HIV during the viral budding has been realized. The c-DNAs encoding the variable regions of the anti-R7V antibody have been cloned from B lymphocytes of a non-progressor patient. Two transfer vectors containing complete coding sequences for heavy and light chains of this antibody were constructed and a recombinant baculovirus was generated by a double recombination between baculovirus DNA and the two transfer vectors. Insect cells infected with this baculovirus produced a complete human anti-R7V immunoglobulin. This recombinant antibody, specific to the R7V peptide, recognizes and neutralizes all clades of HIV1 including resistant viruses, opening new perspectives in anti-HIV therapy.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Baculoviridae / genetics
  • Base Sequence
  • Cell Line
  • HIV Antibodies / therapeutic use*
  • HIV Infections / therapy*
  • HIV-1 / immunology
  • Humans
  • Molecular Sequence Data
  • Neutralization Tests
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / therapeutic use
  • Spodoptera
  • Treatment Failure
  • beta 2-Microglobulin / immunology*

Substances

  • Antibodies, Monoclonal
  • HIV Antibodies
  • Recombinant Proteins
  • beta 2-Microglobulin